I just recieved the following letter:
Congratulations Christina!
Our records indicate that you have met the participant goal set on your fundraising page for your event, Capital of Texas Triathlon which will be held on May 25, 2009.
To date, you have raised $4,500.00.
We know that you set your sights high and went the extra mile to raise funds to benefit The Leukemia & Lymphoma Society’s mission. We thank you.
Our records indicate that you have met the participant goal set on your fundraising page for your event, Capital of Texas Triathlon which will be held on May 25, 2009.
To date, you have raised $4,500.00.
We know that you set your sights high and went the extra mile to raise funds to benefit The Leukemia & Lymphoma Society’s mission. We thank you.
Since its founding in 1949, LLS has invested more than $600 million in blood cancer research. We fund more blood cancer research than all other voluntary health agencies.
An LLS-funded researcher developed Gleevec®, a pill for Chronic Myelogenous Leukemia (CML). Now, more than 95 percent of newly diagnosed CML patients survive more than five years with a good quality of life. LLS was also instrumental in the development of Velcade®, a targeted treatment approved for patients with multiple myeloma and mantle cell lymphoma.
In these tough economic times, charity could not be more important. Your determined fundraising will allow us to invest in our critical mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Thank you again for accelerating our lifesaving efforts.
Sincerely,
John Walter
President & CEO
The Leukemia & Lymphoma Society
An LLS-funded researcher developed Gleevec®, a pill for Chronic Myelogenous Leukemia (CML). Now, more than 95 percent of newly diagnosed CML patients survive more than five years with a good quality of life. LLS was also instrumental in the development of Velcade®, a targeted treatment approved for patients with multiple myeloma and mantle cell lymphoma.
In these tough economic times, charity could not be more important. Your determined fundraising will allow us to invest in our critical mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Thank you again for accelerating our lifesaving efforts.
Sincerely,
John Walter
President & CEO
The Leukemia & Lymphoma Society
Thanks to everyone who helped me get here!!!!! Of the 4 disciplines that TNT help coach their (tri)athletes through...fundraising is the scariest! But at this point we are 1 down with 3 to go...time to swim, bike, run!
Posts
No comments:
Post a Comment